Kailera Therapeutics, Inc. (NASDAQ:KLRA) Short Interest Update

Kailera Therapeutics, Inc. (NASDAQ:KLRA) was the recipient of a large growth in short interest in April. As of April 30th, there was short interest totaling 1,954,558 shares, a growth of ∞ from the April 15th total of 0 shares. Based on an average daily trading volume, of 1,694,308 shares, the short-interest ratio is currently 1.2 days. Currently, 1.6% of the shares of the stock are sold short.

Kailera Therapeutics Price Performance

Shares of KLRA stock opened at $19.55 on Tuesday. Kailera Therapeutics has a fifty-two week low of $19.11 and a fifty-two week high of $28.23.

Insider Activity

In other Kailera Therapeutics news, Director Andrew T. Kaplan bought 8,398,438 shares of the firm’s stock in a transaction dated Monday, April 20th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $134,375,008.00. Following the transaction, the director directly owned 26,255,581 shares of the company’s stock, valued at approximately $420,089,296. This represents a 47.03% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Adam Koppel bought 1,562,500 shares of the firm’s stock in a transaction dated Monday, April 20th. The shares were acquired at an average price of $16.00 per share, for a total transaction of $25,000,000.00. Following the transaction, the director directly owned 22,583,268 shares in the company, valued at approximately $361,332,288. This represents a 7.43% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired 10,460,938 shares of company stock worth $167,375,008 in the last quarter.

Analyst Upgrades and Downgrades

KLRA has been the topic of a number of recent analyst reports. Zacks Research upgraded Kailera Therapeutics to a “hold” rating in a research report on Wednesday, May 13th. Jefferies Financial Group started coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $48.00 target price on the stock. Evercore started coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They issued an “outperform” rating on the stock. Leerink Partners started coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They issued an “outperform” rating and a $36.00 price objective on the stock. Finally, TD Cowen started coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They issued a “buy” rating and a $57.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $42.75.

About Kailera Therapeutics

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.